Consensus Eurofins Scientific SE

Equities

ERF

FR0014000MR3

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 10/07/2025 BST			Pre-market 07:30:24
60.62 ^EUR	+1.54%		59.70	-1.52%

06-27	Eurofins: completes E500m bond issue	CF
06-27	French and Benelux stocks-Factors to watch	RE

Evolution of the Average Target: Eurofins Scientific SE

Evolution of the Target Price: Eurofins Scientific SE

Changes in Analyst Recommendations: Eurofins Scientific SE

7b12afc39b874eefa079.swgnsoQmQGjwmxxsNWZR2RI5whekXbLzewNgApFwp00.2m5j1LdXIR2Cwy8kDQJkkVpNmG7KG9jLEXAuR9AU6iLLOxLQ22ImAYr4JA~b8aa136be6b71461e48e7964683f74e1

Analysts' recommendations: Eurofins Scientific SE

HSBC Downgrades Eurofins Scientific to Hold, Cuts PT	04-25	MT
EUROFINS SCIENTIFIC : Reiterated outlook impresses investors	04-23
EUROFINS : Jefferies still a seller, but raises TP	04-01	CF
Bernstein Upgrades Eurofins Scientific to Outperform, Boosts PT	02-03	MT
EUROFINS SCIENTIFIC : A decent end to FY24: investors jittery with biopharma headwinds	01-31
EUROFINS SCIENTIFIC : Investors are unimpressed despite a decent end to FY24	01-30
EUROFINS SCIENTIFIC : NAV cut by -6.0%	11-28
EUROFINS SCIENTIFIC : Biopharma weighs on Eurofins' Q3 Growth	23/10/24
EUROFINS SCIENTIFIC : EPS upgrade (2024: +8.9%, 2025: +8.0%)	24/08/24
EUROFINS SCIENTIFIC : H1 beat + intact guidance	25/07/24
EUROFINS SCIENTIFIC : Eurofins’ share price tanks after short seller report	24/06/24
EUROFINS SCIENTIFIC : EPS cut (2023: -28.6%, 2024: -18.4%)	31/05/24
EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed	24/04/24
EUROFINS SCIENTIFIC : Lackluster FCF and dividend cut weigh on the share price	28/02/24
Berenberg Cuts Eurofins Scientific PT, Keeps Purchase Rating	16/11/23	MT
Deutsche Bank Upgrades Eurofins Scientific to Hold from Sell, Lowers PT	26/10/23	MT
EUROFINS SCIENTIFIC : Core business drives growth in Q3; FY23 outlook confirmed	24/10/23
Deutsche Bank Trims Eurofins Scientific PT, Keeps Sell Rating	29/08/23	MT
EUROFINS SCIENTIFIC : End of unwinding COVID-19 tailwinds provides a good entry point	23/08/23
EUROFINS SCIENTIFIC : Inflationary headwinds weigh on near-term outlook, but mid-term drivers intact	26/07/23
EUROFINS SCIENTIFIC : EPS cut (2022: -13.6%, 2023: -6.8%)	23/05/23
EUROFINS SCIENTIFIC : Q1 sees robust demand for core business	26/04/23
EUROFINS SCIENTIFIC : Tough macros hit FY22 profitability; lackluster FY23 outlook	01/03/23
EUROFINS SCIENTIFIC : Lackluster Q3 update	19/10/22
EUROFINS SCIENTIFIC : Low quality H1 beat; guidance upgraded but outlook uncertain	28/07/22

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	EUROFINS SCIENTIFIC SE					-1.47%
	LONZA GROUP AG					+15.58%
	BEONE MEDICINES LTD.					+30.61%
	CELLTRION, INC.					+20.93%
	IQVIA HOLDINGS INC.					+15.19%
	ICON PUBLIC LIMITED COMPANY					+15.74%
	ASCENDIS PHARMA A/S					+33.1%
	QIAGEN N.V.					+3.85%
	TEMPUS AI, INC.					+11.91%
	MEDPACE HOLDINGS, INC.					-8.11%
	Average					+13.73%
	Weighted average by Cap.					+16.47%